Skip to main content
An official website of the United States government

autologous mRNA-transfected anti-BCMA-CAR T lymphocytes SYS6020

A preparation consisting of autologous T lymphocytes that have been transfected with lipid nanoparticle (LNP)-mRNA encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous mRNA-transfected anti-BCMA-CAR T lymphocytes SYS6020 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.
Synonym:autologous BCMA-targeted CAR T cells SYS6020
autologous mRNA-lipid nanoparticles-based anti-BCMA CAR T cells SYS6020
autologous mRNA-LNP-based anti-BCMA CAR-T cells SYS6020
Code name:SYS 6020
SYS-6020
SYS6020
Search NCI's Drug Dictionary